# CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

> **NCT01931787** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** 6,8-bis(benzylthio)octanoic acid

## Key facts

- **NCT ID:** NCT01931787
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01931787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01931787, "CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01931787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*